Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemafibrate for liver fibrosis improvement in NAFLD with dyslipidemia
jRCT1041190098Recruiting
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pemafibrate in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and dyslipidemia. Primary endpoint: Improvement of FIB-4 index after treatment. Started Dec 2019; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)dyslipidemia
Beyond the preview
Go deeper on jRCT1041190098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041190098.